NASHUA, N.H., March 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company i... Continue reading

Fourth Quarter Revenues of .5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI ® Product Revenue

ProFound AI® Product Revenue Increased 21% in the Fourth Quarter of 2020 as Compared to 2019 Fourth Quarter Fueled by Launch of ProFound AI ® Risk Assessment Offering

Re... Continue reading

NASHUA, N.H., Feb. 18, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, February 24.

Wednesday February 24th @ 4:30pmET

Domestic:

Continue reading

NASHUA, N.H. – February 16, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life... Continue reading

NASHUA, N.H. – January 19, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor C... Continue reading

New ProFound AI risk software, offering a 2-year projected risk score to be featured

NASHUA, N.H. – January 6, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovat... Continue reading

International Multi-Center Study to Commence January 2021

University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating

First European Patient Treated for Brain Metastasis with Xoft IORT System

NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Santosh Kesari, MD, PhD,... Continue reading

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services’ Network

NASHUA, NH and DALLAS, TX – December 10, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and SolisMammography, the largest independent provider of mammography and breast health services in the United States, today announce... Continue reading

Leading Clinical Experts Discuss Advancing Personalized Breast Cancer Screening and Detection with Newly Launched ProFound AI Risk

Added Market Growth Opportunity Presented by Pioneering AI Breast Cancer Risk Offering

Webinar Taking Place on Monday, December 7 @ 11am ET

NASHUA, N.H. – December 3, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovativ... Continue reading

Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman

NASHUA, N.H. – November 30, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions, including the expanded ProFound AI® platform powered by Panorama, at the 106th Scientif... Continue reading

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types

NASHUA, N.H. – November 25, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Miguel Servet University Hospital in Zaragoza, Spain, will present new data from three clinical studies supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment o... Continue reading

Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji

ProFound AI for DBT Offers Superior Clinical Performance When Compared to Other Commercially Available Breast AI Systems

NASHUA, N.H. – November 24, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,0... Continue reading

Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively

Net Loss Improved by .2 million to .8 million in the Third Quarter of 2020 as Compared to .0 million in the Third Quarter of 2019

New AI Offering Expands Focus from Current Age Based Detection to 2 Year Risk Assessment and Personalized Screening Regimen

Continue reading

NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) --  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, November 5.

Thursday, November 5th @ 4:30pm ET
Domestic:                 800-908-8386
International:           ... Continue reading

Author: JoAnn Pushkin

Breast Cancer Awareness Month is here and a good time to educate women on an important aspect in the detection of breast cancer: breast density. The purpose of breast cancer screening is to detect cancer earlier than it would otherwise be found. When breast cancer is found early, it means less aggressive treatment will be needed and survival rates are highest. Multiple studies have proven that early detection of cancers by mammography reduces breast cancer deaths in women aged 40 to 74.

Continue reading

iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors

NASHUA, N.H. – October 23, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology (ASTRO) Virtual Annual Meeting, October... Continue reading

Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America

NASHUA, N.H. – October 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a distribution agreement with Change Healthcare (NASDAQ: CHNG), a leading independent healthcare te... Continue reading

New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery 

NASHUA, N.H. – October 19, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of recurrent glioblastoma (GBM), wil... Continue reading

NASHUA, N.H., Oct. 16, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host a technology innovation webinar on the current treatment landscape and unmet medical needs for treating cancer, on Wednesday, October 21, 2020, at 10am Eastern Time.

The call will feature presentations by key opinion leaders Santosh Kesari, MD, PhD, John Wayne Cancer Center, Janie Grumley,... Continue reading

Clinically Proven Technology Enhances Breast Cancer Detection, Improves Accuracy

Navicent Health recently announced that they have added the latest development in the fight against breast cancer – iCAD’s Profound AI for digital breast tomosyntheses (DBT), also known as 3D mammography – to their Mammography Program. ProFound AI for DBT was the first artificial intelligence (AI) software for DBT to be FDA-cleared.

DBT, also called three-dimensional (3-D) mammography, is a... Continue reading